Publications
2018
Weiner S, Barris D, Dubin R, Fremed M, Zhang Z, Piperdi S, Zhang W, Maqbool S, Gill J, Roth M, Hoang B, Geller D, Gorlick R, Wesier D. Detection of Circulating Tumor DNA in Patients with Osteosarcoma. Oncotarget. 19;9(16):12695-12704. 1/18. PMCID PMC5849166
Zhang Y, Zvi YS, Batko B, Zaphiros N, O'Donnell EF, Wang J, Sato K, Yang R, Geller DS, Koirala P, Zhang W, Du X, Piperdi S, Liu Y, Zheng D, Roth M, Gill J, Zhang J, Ren T, Gorlick R, Zi X, Hoang BH. Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma. Sci Rep. 2018 24;8(1):14294. PMID: 30250282.
2017
Ren T, Piperdi S, Koirala P, Park A, Zhang W, Ivenitsky D, Zhang Y, Villanueva-Siles E, Hawkins D, Roth M, Gorlick R. CD49b inhibits Osteogenic differentiation and plays an important role in osteosarcoma progression. Oncotarget. 23;8(5):87848-59 E-Pub 10/2017. PMCID: PMC5675677
Morris J, Gill J, Connolly P, Roth M, Chung S, Zhang W, Piperdi S, Hoang B, Yang R, Guzik H, Gorlick R, Geller D. The effect of bone morphogenetic protein-2 on osteosarcoma metastasis. Plos One 12(3), 3/2017. E-Pub 3/2017. PMCID: PMC5338793
Yang Y, Yang R, Roth M, Piperdi S, Zhang E, Dorfman H, Rao P, Park A, Tripathi S, Rosenblum J, Geller D, Hoang B, Gill J, Gorlick R. Genetically Transforming Osteoblasts to Sarcoma: Development of an Osteosarcoma Model. Genes and Cancer (1-2):484-494, 1/2017. E-Pub 1/2017. PMCID: PMC5396624.
Kurmasheva RT, Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Kang M, Reynolds CP, Wu J, Houghton PJ, Smith MA. Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 64(4), 4/2017. e-Pub 10/2016. PMID: 27786412
Lock R, Carol H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Purmal A, Gudkov A, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatr Blood Cancer 64(4), 4/2017. e-Pub 9/2016. PMID: 27650817.
2016
Koirala P, Roth ME, Gill J, Chinai JM, Ewart MR, Piperdi S, Geller DS, Hoang BH, Fatakhova YV, Ghorpade M, Zang X, Gorlick R. HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. Sci Rep 6:31154, 8/2016. e-Pub 8/2016. PMCID: PMC4987662.
Geller DS, Morris J, Revskaya E, Kahn M, Zhang W, Piperdi S, Park A, Koirala P, Guzik H, Hall C, Hoang B, Yang R, Roth M, Gill J, Gorlick R, Dadachova E. Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R). Nucl Med Biol 43(12):812-817, 12/2016. e-Pub 7/2016. PMCID: PMC5118104.
Koirala P, Roth ME, Gill J, Piperdi S, Chinai JM, Geller DS, Hoang BH, Park A, Fremed MA, Zang X, Gorlick R. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep 6:30093, 7/2016. e-Pub 7/2016. PMCID: PMC4960483.
Sampson VB, Vetter NS, Zhang W, Patil PU, Mason RW, George E, Gorlick R, Kolb EA. Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma. Oncotarget. e-Pub 11/2016. PMID: 27863409.
Kang MH, Reynolds CP, Kolb EA, Gorlick R, Carol H, Lock R, Keir ST, Maris JM, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63(10):1744-52, 10/2016. e-Pub 5/2016. PMID: 27238606.
Murphy B, Yin H, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Kurmasheva RT, Dvorchik I, Wu J, Billups CA, Boateng N, Smith MA, Lock RB, Houghton PJ. Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Res 76(19):5798-5809, 10/2016. e-Pub 8/2016. PMCID: PMC5050128.
Gorlick R, Kolb EA, Keir ST, Maris JM, Lock RB, Carol H, Reynolds CP, Kang MH, Billups CA, Collins J, Kurmashev D, Kurmasheva RT, Houghton PJ, Smith MA. Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63(3):443-50, 3/2016. e-Pub 11/2015. PMCID: PMC4724638.
Attiyeh EF, Maris JM, Lock R, Reynolds CP, Kang MH, Carol H, Gorlick R, Kolb EA, Keir ST, Wu J, Landesman Y, Shacham S, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Pediatr Blood Cancer 63(2):276-86, 2/2016. e-Pub 9/2015. PMCID: PMC4722540.
2015
Roth M, Barris DM, Piperdi S, Kuo V, Everts S, Geller D, Houghton P, Kolb EA, Hawthorne T, Gill J, Gorlick R. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Pediatr Blood Cancer 63(1):32-8, 1/2016. e-Pub 8/2015. PMID: 26305408.
Poon VI, Roth M, Piperdi S, Geller D, Gill J, Rudzinski ER, Hawkins DS, Gorlick R. Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma. Clin Sarcoma Res 5(1):4, 2015. e-Pub 1/2015. PMCID: PMC4311500.
Rosenblum JM, Wijetunga NA, Fazzari MJ, Krailo M, Barkauskas DA, Gorlick R, Greally JM. Predictive properties of DNA methylation patterns in primary tumor samples for osteosarcoma relapse status. Epigenetics 10(1):31-9, 2015. e-Pub 1/2015. PMCID: PMC4622015.
Reynolds CP, Kang MH, Maris JM, Kolb EA, Gorlick R, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. Pediatr Blood Cancer 62(11):1897-905, 11/2015. e-Pub 7/2015. PMCID: PMC4758191.
Houghton PJ, Kurmasheva RT, Kolb EA, Gorlick R, Maris JM, Wu J, Tong Z, Arnold MA, Chatterjee M, Williams TM, Smith MA. Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 62(7):1214-21, 7/2015. e-Pub 3/2015. PMCID: PMC4563818.
Geller DS, Singh MY, Zhang W, Gill J, Roth ME, Kim MY, Xie X, Singh CK, Dorfman HD, Villanueva-Siles E, Park A, Piperdi S, Gorlick R. Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2. Clin Cancer Res 21(13):3003-12, 7/2015. e-Pub 12/2014. PMID: 25472999.
Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, Lock RB, Carol H, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 62(6):1106-9, 6/2015. e-Pub 11/2014. PMCID: PMC4405429.
Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res 21(4):819-32, 2/2015. e-Pub 12/2014. PMCID: PMC4587665.
Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 62(1):91-8, 1/2015. e-Pub 9/2014. PMCID: PMC4456187.